Alpha Teknova, Inc. · NASDAQ:TKNO
Alpha Teknova — Q1 2026 Earnings Presentation
18 slides from Alpha Teknova's earnings presentation, May 6, 2026
Slide 1: Financial Results Q1:2026 Slide Supplement
FINANCIAL RESULTS Q1:2026 SLIDE SUPPLEMENT NASDAQ: TKNO May 6, 2026
Slide 2: Forward-looking statements and use of non-GAAP financial measures
Forward-looking statements and use of non-GAAP financial measures Statements in this presentation about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, b
Slide 3: Agenda
Agenda • Welcome • Business Highlights and Updates Stephen Gunstream, President and Chief Executive Officer • Financial Results and 2026 Outlook Matt Lowell, Chief Financial Officer • Q&A © 2026 Alpha Teknova, Inc. ● Financial Results | Q1:2026 ● Slide Supplement 3
Slide 4: We Make Solutions Possible
WE MAKE SOLUTIONS POSSIBLE Leading provider of critical reagents for the discovery, development, and commercialization of novel therapies and diagnostics TOTAL 2025 REVENUE Y/Y REVENUE GROWTH PROJECT ADJ. EBITDA + $40.5M 7% 2027 ACTIVE CUSTOMERS CLINICAL CUSTOMER # THERAPIES 3,000+ % GROWTH SUPPORTE
Slide 5: Our products are fundamental to the life sciences industry
Our products are fundamental to the life sciences industry LIQUID MICROBIAL MOLECULAR AGAR PLATES CULTURE MEDIA BIOLOGY REAGENTS AND SUPPLEMENTS Extensive selection of standard Wide variety of liquid media Offering a vast range of product and specialty pre-poured agar and broths to expand a particul
Slide 6: Primary End Market Segments
2025 REVENUE BREAKDOWN Primary End Market Segments REVENUE BY END MARKET SEGMENT FY:2025 5% Non- Product APPROX. APPROX. APPROX. 1,000 400 1,900* Revenue * * ACCOUNTS ACCOUNTS ACCOUNTS BIOPHARMA AND ~15% LIFE SCIENCE TOOLS OTHER MARKET Other Market CONTRACT AND DIAGNOSTICS SEGMENTS Segments MANUFACT
Slide 7: Revenue by Product Type and Customer End Market
Revenue by Product Type and Customer End Market OTHER Total 2024 Revenue by Product~5% Type and End Market 2025 REVENUE BREAKDOWN CLINICAL • Lab Essentials: ~75% of 2025 Revenue SOLUTIONS § Catalog product revenue comprises ~75% ~20% 15% CLINICAL § Custom product revenue comprises ~25% Catalog SOLUT
Slide 8: Historical Customer Metrics by Product Category
Historical Customer Metrics by Product Category NON-GAAP FIGURES: LAB ESSENTIALS CLINICAL SOLUTIONS Number of 3,374 3,255 3,045 60 Customers1 2,754 2,826 48 2,008 34 21 24 13 2020 2021 2022 2023 2024 2025 2020 2021 2022 2023 2024 2025 Average Revenue $10,578 $10,191 $369 $352 $9,871 $9,761 $9,486 $9
Slide 9: Why we win
Why we win CATALOG BUSINESS FASTER AS A FOUNDATION SMALLER CUSTOM TURNAROUND TIME BATCH SIZES Relative Annual Spend Initial Build Sizes for Custom Time from Order to Shipment by Account Type in 2025 Research and Clinical Orders for Custom Orders 44X 10,000 L MONTHS QC 1,000 L Typical batch size for
Slide 10: Q1:26 Financials
teknova: 01:26 Financials
Slide 11: Q1:2026 Revenue Highlights
Q1:2026 Revenue Highlights Revenue by Category ($M) KEY HIGHLIGHTS $11.1 $9.8 • Total first quarter revenue up 13% 13% y/y $2.1 compared to the same period in $1.2 prior year • Lab Essentials increased 3% compared to the same period in prior year • Clinical Solutions increased 85% $8.1 $8.4 from the
Slide 12: Q1:2026 Income Statement Highlights
Q1:2026 Income Statement Highlights Gross Margin (%) Total OpEx ($M) 34.2% $8.0 $8.1 30.7% Q1:2025 Q1:2026 Q1:2025 Q1:2026 Adjusted EBITDA1 ($M) Diluted EPS ($) ($2.0) ($2.5) ($0.09) ($0.08) Q1:2025 Q1:2026 Q1:2025 Q1:2026 1 Adjusted EBITDA is non-GAAP and adds back stock-based compensation and any
Slide 13: Q1:2026 Cash Flow and Balance Sheet Highlights
Q1:2026 Cash Flow and Balance Sheet Highlights Capital Expenditure ($M) Free Cash Flow1 ($M) ($3.6) ($4.3) $0.2 $0.2 Q1:2025 Q1:2026 Q1:2025 Q1:2026 Cash, Cash Equivalents, and Short-Term Investment was $17.8M as of March 31, 2026 1 Free Cash Flow equals cash provided by (used in) operating activiti
Slide 14: Quarterly Financial Trends
Quarterly Financial Trends Gross Margin1 (%) Total OpEx ($M) $10.2 $7.9 $7.8 $8.0 $7.9 $8.1 $7.5 $7.4 $7.2 39% 31% 32% 34% 29% 30% 31% $8.9 24% 23% $7.8 $7.5 $7.8 $8.0 $7.4 $7.2 $7.4 $8.1 Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Recu
Slide 15: 2026 Outlook and Capital Runway
2026 Outlook and Capital Runway GUIDANCE • Estimate total revenue between $42–44 million, up 6% y/y at the midpoint • We are targeting free cash outflow of less than $10 million for 2026 CAPITAL RUNWAY ASSUMPTIONS • Estimate annualized revenue range of $52-57 million to achieve Adjusted EBITDA break
Slide 16: Supplemental Non-GAAP Reconciliations
Supplemental Non-GAAP Reconciliations
Slide 17: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (unaudited) (in thousands) © 2026 Alpha Teknova, Inc. ● Financial Results | Q1:2026 ● Slide Supplement 17
Slide 18: teknova:
teknova: